CC-122 + nivolumab

CC-122 + nivolumab is an experimental **combination therapy** consisting of CC-122 (avadomide), a novel immunomodulatory small molecule with structural similarity to thalidomide, and nivolumab, a monoclonal antibody immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1)[2][4][1]. - **CC-122 (avadomide)** acts by binding cereblon (CRBN), leading to ubiquitin-mediated degradation of transcription factors IKZF1 and IKZF3, derepressing interferon (IFN)-regulated genes, promoting apoptosis of malignant cells, and modulating T and B cell activity by costimulation and increased IL-2 production[2]. - **Nivolumab** is a human monoclonal antibody inhibiting PD-1 on T cells, blocking interaction with its ligands (PD-L1/PD-L2), resulting in enhanced immune response against tumor cells[5]. The combination aims to leverage CC-122’s immunomodulatory and antineoplastic effects with nivolumab’s checkpoint inhibition to synergistically activate anti-tumor immunity. Clinical development has included dose escalation studies in unresectable hepatocellular carcinoma (HCC), and advanced melanoma[1][4].

Other names

CC-122 + nivolumab